发明名称 Composition and method for treatment of depression and psychosis in humans
摘要 Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.
申请公布号 US9486453(B2) 申请公布日期 2016.11.08
申请号 US201514844021 申请日期 2015.09.03
申请人 Glytech LLC 发明人 Javitt Daniel C.
分类号 A01N43/00;A61K31/553;A61K31/554;A61K31/496;A61K31/42;A61K31/06;A61K31/381;A61K31/55;A61K31/138;A61K45/06;A61K31/431;A61K31/4525;A61K31/519;A61K31/551;A61K31/135 主分类号 A01N43/00
代理机构 JMB Davis Ben-David 代理人 JMB Davis Ben-David
主权项 1. A method for reducing akathisia caused by lurasidone treatment in a subject with bipolar disorder, comprising: administering an akathisia-inducing amount of lurasidone to the subject; once akathisia is induced, continuing to administer lurasidone at a same dosage and frequency that caused akathisia; and administering a therapeutically effective amount of a second composition comprising D-cycloserine (DCS) at a dosage in excess of 500 mg/day, wherein the DCS produces a NMDA receptor antagonistic blood plasma concentration measured at greater than 25 micrograms/mL, thereby reducing akathisia.
地址 Ft. Lee NJ US